Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma

Cristaudo, Alfonso; Foddis, Rudy; Bonotti, Alessandra; Simonini, Silvia; Vivaldi, A; Guglielmi, Giovanni; Ambrosino, Nicolino; Canessa, Pier Aldo; Chella, Antonio; Lucchi, Marco; Mussi, Alfredo; Mutti, Luciano

doi:10.1177/172460081002500307

Cited by 43 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A French study reported higher osteopontin levels in plasma compared to serum, but showed that the ability of osteopontin to discriminate between patients with MM and healthy asbestosexposed subjects was similar using either plasma or serum [28]. However, other studies suggest that plasma is superior to serum when assaying osteopontin levels with a view to discriminating between MM and control patients [58]. On the contrary, the choice of blood sample type has limited effect on soluble mesothelin sensitivity [59].…”

Section: Osteopontinmentioning

confidence: 90%

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma: Table 1–

et al. 2012

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive tumour with poor prognosis whose early diagnosis is difficult. Mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin have attracted attention as biomarkers. The aim of the present review is to provide an overview regarding these candidate biomarkers for MM, and discuss their potential role in today's clinical practice.Mesothelin and MPF have good specificity but sub-optimal sensitivity for detection of MM, being negative both in the sarcomatoid histological sub-type and in almost half of epithelioid mesothelioma, especially in the early stages. Osteopontin is a marker of the duration of asbestos exposure, but lacks specificity for mesothelioma. Several patient characteristics influence the diagnostic accuracy of biomarkers and make the establishment of the ''optimal'' diagnostic threshold difficult. Mesothelin and MPF have proved useful in assessing response to treatment. Combining different markers together may lead to an improvement in diagnostic accuracy, but there is still need for research in this area. Extensive validation and further research is required to improve the use of serum markers in mesothelioma management. In the near future, their application in clinical practice is probably in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.

show abstract

Section: Osteopontinmentioning

confidence: 90%

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma: Table 1–

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Recent studies suggest that OPN and related molecules are a potential target for anticancer therapy. In addition, the plasma concentration of OPN in patients with tumor metastasis is significantly increased in comparison to normal sera, thus its prospects as a marker for evaluating tumor genesis and metastasis are expected (22)(23)(24). Accordingly, further research on OPN is warranted.…”

Section: Discussionmentioning

confidence: 99%

Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry

Li¹,

Yang²,

Zhu

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Osteopontin (OPN), a secreted phosphorylated glycoprotein, has been found to be involved in carcinogenesis, progression and metastasis of several types of cancers. The aim of the present study was to investigate the immunohistochemical expression of OPN in colorectal carcinoma (CRC) and its relationship with clinicopathological parameters and P53. Expression of OPN, Ki-67 and TP53 was detected in 77 cases of CRC by immunohistochemistry and the correlation of the expression of OPN with clinicopathological features, Ki-67 and P53 staining was investigated. Thirty-eight cases (49.4%) of CRC demonstrated OPN overexpression. Overexpression of OPN was associated with lymph node metastasis (P=0.025) and Dukes' stages (P=0.031), but not with gender, histological differentiation, depth of tumor invasion, TNM stages or Ki-67 index. The correlation between expression of OPN and TP53 was statistically significant (P=0.030). In conclusion, OPN is overexpressed in CRC, and plays a role in tumor progression and metastasis, which is possibly regulated by P53.

show abstract

“…For example, the recovery of HE4 rises over 200% after 48 h. Again, OPN is the only marker showing a decline to nearly 80% in recovery supporting our above mentioned findings. Also, Cristaudo et al [30] found an instable performance of OPN after storage of serum samples at room temperature.…”

mentioning

confidence: 99%

Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay

Hermann

Dressen

Schildberg

et al. 2014

WJM

View full text Add to dashboard Cite

AIM:To test the methodical and pre-analytical performance of a new multiplex cancer biomarker panel using magnetic beads. METHODS: The MILLIPLEX® MAP Human Circulating Cancer Biomarker Magnetic Bead Panel 1 comprises the tumor markers carcinoembryonic antigen, alpha-fetoprotein, total prostate-specific antigen, cancer antigen 15-3, cancer antigen 19-9, cancer antigen 125, cytokeratine 19-fragment, β-human chorionic gonadotropin, human epididymis protein 4, osteopontin, prolactin, the cell death and angiogenesis markers soluble Fas, soluble Fas-ligand, tumor necrosis factor related apoptosisinducing ligand, vascular endothelial growth factor and the immunological markers interleukin-6 (IL-6), IL-8, tumor necrosis factor-α, transforming growth factor α, fibroblast growth factor-2, macrophage migration inhibitory factor, leptin, hepatocyte growth factor, and stem cell factor. We determined intra-and inter-assay imprecision as well as dilution linearity using quality controls and serum pools. Furthermore, the stability of the 24 biomarkers examined in this panel was ascertained by testing the influence of different storage temperatures and time span before centrifugation. RESULTS:For all markers measured in the synthetic internal quality controls, the intra-assay imprecision ranged between 2.26% and 9.41%, while for 20 of 24 measured markers in the physiological serum pools, it ranged between 1.68% and 12.87%. The inter-assay imprecision ranged between 1.48%-17.12% for 23 biomarkers in synthetic, and between 4.59%-23.88% for 18 biomarkers in physiological quality controls. Here, single markers with very low concentration levels had increased imprecision rates. Dilution linearity was acceptable (70%-130% recovery) for 20 biomarkers. Regarding pre-analytical influencing factors, most markers were stable if blood centrifugation was delayed or if serum was stored for up to 24 h at 4 ℃ and 25 ℃ after centrifugation. Comparable results were obtained in serum and plasma for most markers. However, great changes were observed for single markers. CONCLUSION: MILLIPLEX® MAP Human Circulating Cancer Biomarker Magnetic Bead Panel 1 assay is a stable and precise method for detection of most biomarkers included in the kit. However, single markers have to be interpreted with care.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Multiplex immunoassay; Tumor marker; Cytokines; Cell death markers; Methodical evaluation Core tip: In this study, the methodological quality of a new research-use-only multiplex magnetic bead assay,

show abstract

Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma

Cited by 43 publications

References 23 publications

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma: Table 1–

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma: Table 1–

Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry

Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay

Contact Info

Product

Resources

About